Biotechnology
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference
These are the first in a series of presentations scheduled through the end of the year sharing advances to SK Biopharmaceutical's targeted protein degradation (TPD) pipeline SEOUL, South Korea and KING OF PRUSSIA, Pa., Sept. 26, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focuse...
2023-09-27 08:30
1495
Latest Updates of Viva's Portfolio Companies
HONG KONG, Sept. 26, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the su...
2023-09-26 21:06
1806
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md., Sept. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
2023-09-26 20:30
1581
WuXi Vaccines Launches Its First Vaccines CDMO Site in China
SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou,China. The opening will add drug substanc...
2023-09-26 15:41
1484
Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
--Based on prespecified interim analysis condition, 120 patients are likely to lead sufficient events for interim analysis of progression-free survival (PFS) HANGZHOU and SHAOXING, China, Sept. 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the completion o...
2023-09-26 08:10
2142
Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch
* Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support. Chime will also supply the commercial production once the produc...
2023-09-25 20:15
1485
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
SINGAPORE, Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
2023-09-25 19:00
1502
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychi...
2023-09-25 09:00
2488
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs...
2023-09-25 07:41
1998
MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment
----- YL201 Phase I/II Investigators Meeting was successfully held in Guangzhou, China GUANGZHOU, China, Sept. 23, 2023 /PRNewswire/ -- On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered inGuangzhou to participate in the YL201 P...
2023-09-23 18:29
2593
Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development
* Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein drug. Chime Biologics will provide development and manufacturing services to Panolos Bioscience for PB203, a next-generation immuno-oncology drug. WUHAN, China...
2023-09-22 20:15
1639
MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil
FOSTER CITY, Calif., Sept. 22, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has g...
2023-09-22 16:41
1454
FDA Grants Fast Track Designation to 9MW3011
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Fast Track Designation (FTD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (P...
2023-09-22 08:00
1716
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced its partnership with Aditum Bio to create Celexor Bio (Celexor), a ne...
2023-09-21 21:00
4300
Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Products Administration (NMPA) has granted priority review status to golidocitinib, Dizal's investigational JAK1-only inhibitor, for the treatment of relapsed or refractory peripheral T-cell lymphoma (r...
2023-09-21 20:26
1605
VEDU Announces New Business Development and Management Team Changes
TORONTO, Sept. 21, 2023 /PRNewswire/ -- Visionary Education Technology Holdings Group Inc. (the "Company") (NASDAQ: VEDU), a private education provider located inCanada, with subsidiaries in Canada and market partners in China, today announced the Company has decided to diversify its business int...
2023-09-21 20:00
3783
AVANCE CLINICAL APPOINTS US-BASED EXECUTIVES - SVP SCIENTIFIC AND REGULATORY AFFAIRS, AND DIRECTOR BUSINESS DEVELOPMENT
ADELAIDE, Australia and RALEIGH, N.C., Sept. 21, 2023 /PRNewswire/ -- Avance
Clinical, the award-winning Australian and North American market-leading CRO
for biotechs, announces two key appointments in the US to support its continued
global growth.
2023-09-21 19:30
1664
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
- The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). - ATG-031,discovered and developed in-house by Antengene,is the world's firs...
2023-09-21 18:05
2111
Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of the treatment of metastatic pancreat...
2023-09-21 16:00
1497
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB
HANGZHOU, China, Sept. 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, today announced the successful completion of Series C2 financing. This round of financing was jointly participated by the Shaox...
2023-09-21 08:00
2656
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116